Lassen Therapeutics, Inc.

Anaptysbio, Inc.

Lassen Therapeutics 1, Inc.

Helen Toni Jun

David J King

Robert A Horlick

Marilyn Kehry

Peter M Bowers

Deborah A Witherden

Mark G Barrett

Magdalena S Willen

Christine M Chidester

Provided are antibodies that bind to interleukin-18 binding protein (IL-18BP) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers and other diseases.

Anti-IL-18BP antibodies

Provided are antibodies and antigen binding fragments thereof that bind to human interleukin-11 receptor subunit α (IL-11Rα) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers, inflammatory diseases, autoimmune diseases, and others.

Method of treating an interleukin-11-associated or -mediated fibrotic disease or condition by administering an anti-interleukin-11 receptor subunit alpha (IL-11RA) antibody

Anti-interleukin-11 receptor subunit α (IL-11Rα) antibodies

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the Lymphocyte Activation Gene-3 (LAG-3). The invention provides a LAG-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the LAG-3-binding agent to treat a disorder or disease that is responsive to LAG-3 inhibition, such as cancer or an infectious disease.

Antibodies directed against lymphocyte activation gene 3 (LAG-3)

Growing community of inventors

San Diego, CA, United States of America

Helen Toni Jun